About Niagen Bioscience Inc
- Industry: Consumer products
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.niagenbioscience.com/
Frequently Asked Questions
What is the 52-week range for NAGE?
The 52-week high is $9.28 and the 52-week low is $2.67.
What is the P/E ratio for NAGE?
The Price to Earnings (P/E) ratio is 13.34.
What is the dividend yield for NAGE?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is 20.50%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is 12.39%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 6.63.
Analyst Recommendation Trends
Wall Street analyst consensus for NAGE over the last few months:
Latest NAGE News
Niagen Bioscience Puts 25 Years of NAD+ Science Behind "Don't Get Old. Age Better.®" a New Campaign for its Niagen® Brand Featuring Legendary Surfer Kelly Slater
LOS ANGELES, October 01, 2026--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the launch of "Don't Get Old. Age Better.®," a new brand campaign for its Niagen® (patented nicotinamide riboside, or NR) brand and sub-brands Tru Niagen® and Niagen Plus™, featuring 11-time world champion surfer Kelly Slater and more than 20 partners, across sports, entertainment, and medicine. The c
Niagen Bioscience (NAGE): Can Its NAD+ Business Drive the Next Leg of Growth?
Gabelli Investment Management Firm recently released its “Mini Mites Fund” second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The Fund benefited from a strong investment environment for global small- and micro-cap stocks in the second quarter of 2026, as AI adoption, reshoring, supply-chain reconfiguration, and strength in semiconductor, aerospace, defense, […]
Niagen Bioscience Announces Start-Up Agreement With Mass General Brigham (MGB) Investigators For First-Of-Its-Kind Healthy Aging Clinical Trial
LOS ANGELES, September 30, 2026--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced a Start-Up Agreement with Mass General Brigham (MGB) to begin detailed planning for what is envisioned to be the largest and most comprehensive clinical trial of Niagen (patented nicotinamide riboside or NR) to date.
Niagen Bioscience Enters Start-Up Agreement With Mass General Brigham To Plan The Largest And Most Comprehensive Clinical Trial Of Niagen To Date
As an investigator-led study, MGB is developing the proposed trial in collaboration with the Niagen Research Program, the Company’s external research program supporting independent and collaborative research on
Transcript: Niagen Bioscience Q2 2026 Earnings Conference Call
Niagen Bioscience (NASDAQ:NAGE) held its second-quarter earnings conference call on Tuesday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For real-time access to
Niagen Bioscience: Down 68%, But Still Not Quite A Buy
Niagen Bioscience remains a hold as strong fundamentals and a debt-free balance sheet are offset by limited valuation upside.
Newly Published Preclinical Study Demonstrates CD38 as a Driver of Age-Related NAD+ Decline, Older Mothers Have Lower NAD+ Levels in Placental Tissue, and NAD+ Restoration with Nicotinamide Riboside (NR) Improves Pregnancy Outcomes
LOS ANGELES, September 21, 2026--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces the publication of independent preclinical research in Nature Communications led by a team at Sichuan Agricultural University identifying the CD38 enzyme as a primary driver of NAD+ decline in aging tissue, and that nicotinamide riboside (NR) restored NAD+ and improved placental, fetal, and offsprin
Niagen Bioscience Highlights Preclinical Research Linking CD38-Driven NAD+ Depletion To Placental Aging; NOTE: Niagen Bioscience Did Not Conduct, Fund, Or Design This Study, And The NR Used Was Not The Company’s Niagen Ingredient
Preclinical study results showcase that CD38, an NAD-consuming enzyme more active with age and inflammation, leads to NAD+ depletion in placental tissue, while restoring NAD+ with the precursor NR improved placental,
Niagen Bioscience Engages Veteran Pharmaceutical Executives and Biotechnology Experts to Support Drug Development Program and Strategic Business Growth
LOS ANGELES, September 17, 2026--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announces today that its wholly owned subsidiary, NAD Pharmaceuticals Corp., has engaged Red Sky Partners, a life sciences strategic advisory firm, to support the advancement of NB4168, the Company’s small molecule investigational drug candidate, targeting rare genetic diseases and aging-related disorders. The Comp
Niagen Bioscience to Present at Canaccord Genuity’s Well Summit
LOS ANGELES, September 10, 2026--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Ozan Pamir, will participate in Canaccord Genuity’s Well Summit, taking place from September 28 to 30, 2026, in New York.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-06-30 | Lopez Carlos Luis | +2,314 | $2.71 | $6,271 |
| 2026-06-30 | Pamir Ozan | +4,255 | $2.71 | $11,531 |
| 2026-06-30 | Fried Robert N | +1,106 | $2.71 | $2,997 |
| 2026-06-24 | Shahbazi Hamed | +31,746 | - | - |
| 2026-06-24 | Cohen Ann | +31,746 | - | - |
| 2026-06-24 | Ng Wang Yu Gary | +31,746 | - | - |
| 2026-06-24 | Patrick Kristin | +31,746 | - | - |
| 2026-06-24 | YU Wing Tak Wendy | +31,746 | - | - |
| 2026-06-24 | Jaksch Frank L Jr | +31,746 | - | - |
| 2026-06-24 | Rubin Steven D | +31,746 | - | - |
| 2026-04-24 | Fried Robert N | -20,000 | - | - |
| 2026-04-24 | Fried Robert N | +20,000 | $2.61 | $52,200 |
| 2026-02-19 | Lopez Carlos Luis | +41,420 | - | - |
| 2026-02-19 | Pamir Ozan | +62,131 | - | - |
| 2026-02-19 | Fried Robert N | +503,937 | - | - |
| 2025-11-14 | Pamir Ozan | +2,220 | $6.85 | $15,207 |
| 2025-11-14 | Pamir Ozan | +4,465 | $6.81 | $30,407 |